Clinical Trials Using Belinostat
Clinical trials are research studies that involve people. The clinical trials on this list are studying Belinostat. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Pevonedistat and Belinostat in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial studies side effects and best dose of pevonedistat and belinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back or does not respond to treatment. Drugs used in chemotherapy, such as pevonedistat and belinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia
Belinostat and Zidovudine for the Treatment of HTLV-I Positive T-Cell Leukemia or Lymphoma
This phase II trial studies the side effects and how well belinostat and zidovudine work for the treatment of HTLV-I positive T cell leukemia or lymphoma. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may kill cancer cells and cause viruses that are inactive in cells to become active. Zidovudine is an antiviral agent. When given with interferon alpha may help lower the levels and control disease so that cancer does not get worse or come back. Interferon alpha is a man-made copy of a protein that is produced by the body in response to infections. Interferon alpha may help the immune system fight disease and may slow or stop the growth of cancer cells. Giving belinostat and zidovudine may work better in eliminating disease and making cancer disappear from the body compared to chemotherapy or antiviral drugs.
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
Location: Mayo Clinic, Rochester, Minnesota